| Name | Title | Contact Details |
|---|
First Care Medical Services is a Fosston, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Caregiver Homes from Seniorlink is an innovative, proven model of full-time in-home care and support for elders and individuals with disabilities that offers families a quality alternative to care that depends on facilities or home health aides. Through financial assistance, as well as dedicated care managers and nurses who provide daily support and monitoring to ensure success for both the consumer and caregiver, Caregiver Homes makes it possible for families to provide around-the-clock care for elders and those with disabilities. We began Caregiver Homes in 2005 because we felt that caring for loved ones at home should be an option that is available to families. And we believed that caregivers should have access to the support they need. In addition to giving families a choice, caregiving at home is more cost effective for Medicaid than nursing facilities. Through a pilot program in Massachusetts, Caregiver Homes tested this new model of care: 24/7 care by a professionally supported, paid live-in caregiver of the consumer`s choosing. The pilot proved that elders needing help with three or more personal care needs-often with multiple chronic conditions—could be cared for at home at half the cost of nursing facility placement. In response to the pilot, Massachusetts made Structured Family Caregiving—known in the Commonwealth as Enhanced Adult Foster Care—a permanent part of its Medicaid program for individuals with complex care needs from all backgrounds. Caregiver Homes took on its first consumer in February 2007. Since 2007, enrollment has grown rapidly as awareness of Caregiver Homes has grown. Caregiver Homes now proudly serves more than 2,300 consumers across Massachusetts, Rhode Island (2010), Ohio (2012), Indiana (2013), and Connecticut (2014).
Osmotics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Osmotics is based in Denver, CO. You can find more information on Osmotics at www.osmotics.com
BI Nutraceuticals is a solutions-based botanical manufacturer, custom contract manufacturer, and supplier to the Dietary Supplement, Food & Beverage, Pharmaceutical, Personal Care, and Pet Care Industries. We are the leading manufacturer of whole herb powders and teas, standardized and drug ratio extracts, vitamins, minerals, amino acids, custom blends, drum-to-hopper (D-T-H) formulations, and granular ingredients. BI Nutraceuticals is committed to providing top-quality ingredients, starting even before the raw material comes through the door with our in-depth industry knowledge and distinguished vendor qualification program. The moment we receive the material it undergoes BI`s Protexx HP™ Green Steam™ sterilization, our patented high pressure, low moisture steam sterilization process, and a complete array of tests including Identilok®, our proprietary Species Genus identificaiton technology. The result is a product that meets a quality standard above all others. Quality is our competitive differentiator and the single most important ingredient we sell.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.